Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
3 critical factors of successfully deploying a single ELN in your lab
Download this use case to learn the 3 key factors...
Continuous environmental monitoring — compliance and best practice tips
Automated environmental monitoring systems are now a critical element in many laboratory...
Flow cytometric chromosome classification
Flow cytometric chromosome classification has been routinely used in the analysis of mammalian...
